Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aterian, Inc.ATER · Entity 8078 | Director · Chief Executive Officer · 10% owner | July 17, 2026 | September 11, 2026 |
| CapForce Inc.OPGN · Entity 9776 | Director · Chief Executive Officer · 10% owner | July 30, 2024 | August 01, 2024 |
| FiEE, Inc.MINM · Entity 7395 | Director · 10% owner | February 18, 2025 | March 10, 2025 |
| Indaptus Therapeutics, Inc.INDP · Entity 6530 | Director | March 23, 2026 | March 24, 2026 |
| KALA BIO, Inc.KALA · Entity 7964 | Director · Chief Executive Officer | December 18, 2025 | December 22, 2025 |
| Quantum Cyber N.V.QUCY · Entity 6633 | Director · Chief Executive Officer · 10% owner | August 05, 2026 | August 07, 2026 |
| Sow Good Inc.SOWG · Entity 6993 | Director | March 31, 2026 | April 02, 2026 |
| TITAN PHARMACEUTICALS INCTTNP · Entity 74432 | Director · Chief Executive Officer | July 26, 2023 | July 31, 2023 |
| Tracon Pharmaceuticals, Inc.TCON · Entity 91134 | Chief Business Dev Officer | May 07, 2024 | May 13, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aterian, Inc.
Report date July 17, 2026 · Filed September 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,737,500 |
Reported balance
After 2026-08-04 transaction · row 1
1 source rowRow 1 · 2026-08-04 · Conversion · Acquired 875,000 · Balance 6,737,500 |
| Series AAA Convertible Non-Redeemable Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.01 | Direct | 1,750,000 |
Reported balance
After 2026-07-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-17 · Grant · Acquired 1,750,000 · Balance 1,750,000 F1: On July 17, 2026, the Reporting Person acquired 1,750,000 shares of Series AAA Convertible Non-Redeemable Preferred Stock at $2.00 per share (the "Series AAA Preferred Shares"), for an aggregate purchase price of $3,500,000, pursuant to the Securities Purchase Agreement dated April 27, 2026. Following receipt of the requisite stockholder approvals, each Series AAA Preferred Share may be converted into 135.1 shares of Common Stock (up to 236,425,000 shares in the aggregate) at a conversion price of $0.0148, for no additional consideration. F2: Each of the Series AAA Preferred Shares and Series AA Convertible Non-Redeemable Preferred Stock (the "Series AA Preferred Shares") are perpetual and therefore have no expiration date. |
| Series AA Convertible Non-Redeemable Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.26 | Direct | 6,737,500 |
Reported balance
After 2026-08-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-04 · Conversion · Disposed 875,000 · Balance 6,737,500 F2: Each of the Series AAA Preferred Shares and Series AA Convertible Non-Redeemable Preferred Stock (the "Series AA Preferred Shares") are perpetual and therefore have no expiration date. F3: Following stockholder approval on July 17, 2026, the Series AA Preferred Shares are convertible into shares of Common Stock at the option of the Reporting Person for no additional consideration. On August 4, 2026, the Reporting Person converted 6,737,500 shares of his Series AA Preferred Shares. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 17, 2026, the Reporting Person acquired 1,750,000 shares of Series AAA Convertible Non-Redeemable Preferred Stock at $2.00 per share (the "Series AAA Preferred Shares"), for an aggregate purchase price of $3,500,000, pursuant to the Securities Purchase Agreement dated April 27, 2026. Following receipt of the requisite stockholder approvals, each Series AAA Preferred Share may be converted into 135.1 shares of Common Stock (up to 236,425,000 shares in the aggregate) at a conversion price of $0.0148, for no additional consideration.
F2: Each of the Series AAA Preferred Shares and Series AA Convertible Non-Redeemable Preferred Stock (the "Series AA Preferred Shares") are perpetual and therefore have no expiration date.
F3: Following stockholder approval on July 17, 2026, the Series AA Preferred Shares are convertible into shares of Common Stock at the option of the Reporting Person for no additional consideration. On August 4, 2026, the Reporting Person converted 6,737,500 shares of his Series AA Preferred Shares.
CapForce Inc.
Report date July 30, 2024 · Filed August 01, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Series E Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-07-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-07-30 · Sale · Disposed 550,000 · Balance 0 F1: On July 30, 2024, David E. Lazar (the "Reporting Person") entered into a securies purchase agreement with AEI Capital Group, a third party, pursuant to which the Reporting Person sold (i) 550,000 shares of Series E Convertible Preferred Stock (the "Series E Preferred Stock") of OpGen, Inc. (the "Company") and (ii) the rights to acquire an additional 2,450,000 shares of Series E Preferred Stock for $2,450,000 pursuant to an agreement between the Reporting Person and the Company. F2: The shares of Series E Preferred Stock are convertible at the option of the Reporting Person for no additional consideration. F3: The Series E Preferred Stock is perpetual and therefore has no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 30, 2024, David E. Lazar (the "Reporting Person") entered into a securies purchase agreement with AEI Capital Group, a third party, pursuant to which the Reporting Person sold (i) 550,000 shares of Series E Convertible Preferred Stock (the "Series E Preferred Stock") of OpGen, Inc. (the "Company") and (ii) the rights to acquire an additional 2,450,000 shares of Series E Preferred Stock for $2,450,000 pursuant to an agreement between the Reporting Person and the Company.
F2: The shares of Series E Preferred Stock are convertible at the option of the Reporting Person for no additional consideration.
F3: The Series E Preferred Stock is perpetual and therefore has no expiration date.
FiEE, Inc.
Report date February 18, 2025 · Filed March 10, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,681,980 |
Reported balance
After 2025-02-18 transaction · row 1
1 source rowRow 1 · 2025-02-18 · Grant · Acquired 1,200,000 · Balance 2,681,980 F1: Shares acquired pursuant to an Amended and Restated Securities Purchase Agreement (the "Purchase Agreement") by and among the Reporting Person, FiEE, Inc. (the "Issuer") and certain purchasers party thereto (the "Purchasers"), pursuant to which the Reporting Person (i) acquired 1,200,000 newly issued shares of common stock of the Issuer and (ii) sold (A) 2,219,447 shares of Series A Convertible Preferred Stock ("Series A Preferred Stock") and (B) a warrant to purchase up to an additional 2,800,000 shares of common stock, in exchange for an aggregate purchase price of $500,000 paid by the Purchasers to the Issuer, as fully set forth in the Purchase Agreement. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 85,910 |
Reported balance
After 2025-02-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-02-18 · Sale · Disposed 2,219,447 · Balance 85,910 F2: The shares of Series A Preferred Stock are convertible at any time at the option of the holder for no additional consideration. F4: Shares sold pursuant to the Purchase Agreement by and among the Reporting Person, the Issuer and the Purchasers, pursuant to which the Reporting Person (i) acquired 1,200,000 newly issued shares of common stock of the Issuer and (ii) sold (A) 2,219,447 shares of Series A Preferred Stock and (B) a warrant to purchase up to an additional 2,800,000 shares of common stock, in exchange for an aggregate purchase price of $500,000 paid by the Purchasers to the Issuer, as fully set forth in the Purchase Agreement. F3: The Series A Preferred Stock is perpetual and therefore has no expiration date. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2029-01-29 | Direct | 0 |
Reported balance
After 2025-02-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-02-18 · Sale · Disposed 2,800,000 · Balance 0 F5: Warrants sold pursuant to the Purchase Agreement by and among the Reporting Person, the Issuer and the Purchasers, pursuant to which the Reporting Person (i) acquired 1,200,000 newly issued shares of common stock of the Issuer and (ii) sold (A) 2,219,447 shares of Series A Preferred Stock and (B) a warrant to purchase up to an additional 2,800,000 shares of common stock, in exchange for an aggregate purchase price of $500,000 paid by the Purchasers to the Issuer, as fully set forth in the Purchase Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares acquired pursuant to an Amended and Restated Securities Purchase Agreement (the "Purchase Agreement") by and among the Reporting Person, FiEE, Inc. (the "Issuer") and certain purchasers party thereto (the "Purchasers"), pursuant to which the Reporting Person (i) acquired 1,200,000 newly issued shares of common stock of the Issuer and (ii) sold (A) 2,219,447 shares of Series A Convertible Preferred Stock ("Series A Preferred Stock") and (B) a warrant to purchase up to an additional 2,800,000 shares of common stock, in exchange for an aggregate purchase price of $500,000 paid by the Purchasers to the Issuer, as fully set forth in the Purchase Agreement.
F2: The shares of Series A Preferred Stock are convertible at any time at the option of the holder for no additional consideration.
F3: The Series A Preferred Stock is perpetual and therefore has no expiration date.
F4: Shares sold pursuant to the Purchase Agreement by and among the Reporting Person, the Issuer and the Purchasers, pursuant to which the Reporting Person (i) acquired 1,200,000 newly issued shares of common stock of the Issuer and (ii) sold (A) 2,219,447 shares of Series A Preferred Stock and (B) a warrant to purchase up to an additional 2,800,000 shares of common stock, in exchange for an aggregate purchase price of $500,000 paid by the Purchasers to the Issuer, as fully set forth in the Purchase Agreement.
F5: Warrants sold pursuant to the Purchase Agreement by and among the Reporting Person, the Issuer and the Purchasers, pursuant to which the Reporting Person (i) acquired 1,200,000 newly issued shares of common stock of the Issuer and (ii) sold (A) 2,219,447 shares of Series A Preferred Stock and (B) a warrant to purchase up to an additional 2,800,000 shares of common stock, in exchange for an aggregate purchase price of $500,000 paid by the Purchasers to the Issuer, as fully set forth in the Purchase Agreement.
Indaptus Therapeutics, Inc.
Report date March 23, 2026 · Filed March 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Series AA Convertible Non-Redeemable Preferred StockSEC Table II · derivative / convertible security | Direct | 103,200 |
Reported balance
After 2026-03-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-23 · Sale · Disposed 196,800 · Balance 103,200 F1: On March 19, 2026, David E. Lazar (the "Reporting Person") entered into a Securities Purchase Agreement pursuant to which the Reporting Person sold all of his title and interest in (i) all 700,000 shares of Series AAA Preferred Stock (convertible into an aggregate of 105,000,000 shares of the Issuer's common stock) held by the Reporting Person and (ii) 196,800 shares of the Reporting Person's Series AA Preferred Stock (convertible into an aggregate of 3,936,000 shares of the Issuer's common stock), as well as all of the Reporting Person's rights, title and interest in the Series AA Preferred Stock and Series AAA Preferred Stock under a securities purchase agreement dated December 22, 2025 (the "March 2026 Transaction"). The closing of the March 2026 Transaction occurred on March 23, 2026. Following the March 2026 Transaction, the Reporting Person retained 103,200 shares of Series AA Preferred Stock, convertible into an aggregate of 2,064,000 shares of the Issuer's common stock. F2: The Series AA Preferred Stock is convertible at the option of the holder for no additional consideration. F3: The Series AA Preferred Stock is perpetual and therefore has no expiration date. |
| Series AAA Convertible Non-Redeemable Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-03-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-23 · Sale · Disposed 700,000 · Balance 0 F1: On March 19, 2026, David E. Lazar (the "Reporting Person") entered into a Securities Purchase Agreement pursuant to which the Reporting Person sold all of his title and interest in (i) all 700,000 shares of Series AAA Preferred Stock (convertible into an aggregate of 105,000,000 shares of the Issuer's common stock) held by the Reporting Person and (ii) 196,800 shares of the Reporting Person's Series AA Preferred Stock (convertible into an aggregate of 3,936,000 shares of the Issuer's common stock), as well as all of the Reporting Person's rights, title and interest in the Series AA Preferred Stock and Series AAA Preferred Stock under a securities purchase agreement dated December 22, 2025 (the "March 2026 Transaction"). The closing of the March 2026 Transaction occurred on March 23, 2026. Following the March 2026 Transaction, the Reporting Person retained 103,200 shares of Series AA Preferred Stock, convertible into an aggregate of 2,064,000 shares of the Issuer's common stock. F4: The Series AAA Preferred Stock is convertible at the option of the holder for no additional consideration. F5: The Series AAA Preferred Stock is perpetual and therefore has no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 19, 2026, David E. Lazar (the "Reporting Person") entered into a Securities Purchase Agreement pursuant to which the Reporting Person sold all of his title and interest in (i) all 700,000 shares of Series AAA Preferred Stock (convertible into an aggregate of 105,000,000 shares of the Issuer's common stock) held by the Reporting Person and (ii) 196,800 shares of the Reporting Person's Series AA Preferred Stock (convertible into an aggregate of 3,936,000 shares of the Issuer's common stock), as well as all of the Reporting Person's rights, title and interest in the Series AA Preferred Stock and Series AAA Preferred Stock under a securities purchase agreement dated December 22, 2025 (the "March 2026 Transaction"). The closing of the March 2026 Transaction occurred on March 23, 2026. Following the March 2026 Transaction, the Reporting Person retained 103,200 shares of Series AA Preferred Stock, convertible into an aggregate of 2,064,000 shares of the Issuer's common stock.
F2: The Series AA Preferred Stock is convertible at the option of the holder for no additional consideration.
F3: The Series AA Preferred Stock is perpetual and therefore has no expiration date.
F4: The Series AAA Preferred Stock is convertible at the option of the holder for no additional consideration.
F5: The Series AAA Preferred Stock is perpetual and therefore has no expiration date.
KALA BIO, Inc.
Report date December 18, 2025 · Filed December 22, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Convertible LoanSEC Table II · derivative / convertible security · Conversion / exercise price $1.02 | Direct | 0 |
Reported balance
After 2025-12-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-12-18 · Other · Disposed 368,614 · Balance 0 F3: On November 9, 2025, the Reporting Person, as "Lender", entered into a Convertible Loan Agreement (the "Agreement") with Issuer pursuant to which Lender agreed to loan the Issuer up to an amount of $375,000. Pursuant to the Agreement, the Lender had the right in its discretion at any time prior to the full repayment of the Loan Amount (as defined in the Agreement) to the Lender, to convert all or any of the then outstanding and unpaid portion of the Loan Amount into Issuer's common stock at the "Conversion Price" (as defined in the Agreement). On December 18, 2025, the Issuer repaid the full Loan Amount to the Reporting Person in cash. F2: Not applicable. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2025-12-18 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 F1: No shares of common stock are beneficially owned. |
Filing footnotes · ownership attribution and instrument terms
F1: No shares of common stock are beneficially owned.
F2: Not applicable.
F3: On November 9, 2025, the Reporting Person, as "Lender", entered into a Convertible Loan Agreement (the "Agreement") with Issuer pursuant to which Lender agreed to loan the Issuer up to an amount of $375,000. Pursuant to the Agreement, the Lender had the right in its discretion at any time prior to the full repayment of the Loan Amount (as defined in the Agreement) to the Lender, to convert all or any of the then outstanding and unpaid portion of the Loan Amount into Issuer's common stock at the "Conversion Price" (as defined in the Agreement). On December 18, 2025, the Issuer repaid the full Loan Amount to the Reporting Person in cash.
Quantum Cyber N.V.
Report date August 05, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 55,057,500 |
Ending reported balance
After 2026-08-05 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-08-05 · Conversion · Acquired 9,000,000 · Balance 9,000,000 Row 2 · 2026-08-05 · Conversion · Acquired 9,000,000 · Balance 18,000,000 Row 3 · 2026-08-05 · Conversion · Acquired 9,000,000 · Balance 27,000,000 Row 4 · 2026-08-05 · Conversion · Acquired 28,057,500 · Balance 55,057,500 |
| Series A Preferred SharesSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-08-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-08-05 · Conversion · Disposed 1,000,000 · Balance 0 F1: Following receipt by Quantum Cyber N.V. (the "Company") of stockholder approval on April 22, 2026, each class of Preferred Shares became convertible into Ordinary Shares at the option of David E. Lazar (the "Reporting Person") for no additional consideration. On August 5, 2026, the Reporting Person submitted notices of conversion to convert all of his Series A Preferred Shares, Series B Preferred Shares, and Series C Preferred Shares, and 124,700 of his Series D Preferred Shares, into Ordinary Shares. F2: Each class of Preferred Shares is perpetual and therefore has no expiration date. |
| Series B Preferred SharesSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-08-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-05 · Conversion · Disposed 1,000,000 · Balance 0 F1: Following receipt by Quantum Cyber N.V. (the "Company") of stockholder approval on April 22, 2026, each class of Preferred Shares became convertible into Ordinary Shares at the option of David E. Lazar (the "Reporting Person") for no additional consideration. On August 5, 2026, the Reporting Person submitted notices of conversion to convert all of his Series A Preferred Shares, Series B Preferred Shares, and Series C Preferred Shares, and 124,700 of his Series D Preferred Shares, into Ordinary Shares. F2: Each class of Preferred Shares is perpetual and therefore has no expiration date. |
| Series C Preferred SharesSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-08-05 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-08-05 · Conversion · Disposed 1,000,000 · Balance 0 F1: Following receipt by Quantum Cyber N.V. (the "Company") of stockholder approval on April 22, 2026, each class of Preferred Shares became convertible into Ordinary Shares at the option of David E. Lazar (the "Reporting Person") for no additional consideration. On August 5, 2026, the Reporting Person submitted notices of conversion to convert all of his Series A Preferred Shares, Series B Preferred Shares, and Series C Preferred Shares, and 124,700 of his Series D Preferred Shares, into Ordinary Shares. F2: Each class of Preferred Shares is perpetual and therefore has no expiration date. |
| Series D Preferred SharesSEC Table II · derivative / convertible security | Direct | 875,300 |
Reported balance
After 2026-08-05 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-08-05 · Conversion · Disposed 124,700 · Balance 875,300 F1: Following receipt by Quantum Cyber N.V. (the "Company") of stockholder approval on April 22, 2026, each class of Preferred Shares became convertible into Ordinary Shares at the option of David E. Lazar (the "Reporting Person") for no additional consideration. On August 5, 2026, the Reporting Person submitted notices of conversion to convert all of his Series A Preferred Shares, Series B Preferred Shares, and Series C Preferred Shares, and 124,700 of his Series D Preferred Shares, into Ordinary Shares. F2: Each class of Preferred Shares is perpetual and therefore has no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Following receipt by Quantum Cyber N.V. (the "Company") of stockholder approval on April 22, 2026, each class of Preferred Shares became convertible into Ordinary Shares at the option of David E. Lazar (the "Reporting Person") for no additional consideration. On August 5, 2026, the Reporting Person submitted notices of conversion to convert all of his Series A Preferred Shares, Series B Preferred Shares, and Series C Preferred Shares, and 124,700 of his Series D Preferred Shares, into Ordinary Shares.
F2: Each class of Preferred Shares is perpetual and therefore has no expiration date.
Sow Good Inc.
Report date March 31, 2026 · Filed April 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,740,000 |
Reported balance
After 2026-03-31 transaction · row 1
1 source rowRow 1 · 2026-03-31 · Grant · Acquired 5,740,000 · Balance 5,740,000 F3: Amount represents 5,740,000 shares received as a result of the conversion of 410,000 Series AA Convertible, Non-Redeemable Preferred Stock at a conversion price of $0.14286. |
| Series AA Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.14 | Direct | 1,090,000 |
Reported balance
After 2025-12-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-12-31 · Exercise / conversion · Disposed 410,000 · Balance 1,090,000 F1: On December 31, 2025, Sow Good Inc. (the "Company") entered into a Securities Purchase Agreement (the "Agreement") with David Lazar, pursuant to which the Company issued 1,500,000 shares of Series AA Preferred Stock to Mr. Lazar at $2 per preferred share. The Series AA Preferred Stock is not convertible into common stock until after stockholder approval, at which point the shares will convert to 21,000,000 shares of common stock with a conversion price of $0.14286 per share. The Agreement and the issuance of the Series AA Preferred Stock were approved by the Company's board of directors and did not involve the exchange of consideration between the Company and Mr. Lazar beyond the terms set forth in the Agreement. F2: Not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 31, 2025, Sow Good Inc. (the "Company") entered into a Securities Purchase Agreement (the "Agreement") with David Lazar, pursuant to which the Company issued 1,500,000 shares of Series AA Preferred Stock to Mr. Lazar at $2 per preferred share. The Series AA Preferred Stock is not convertible into common stock until after stockholder approval, at which point the shares will convert to 21,000,000 shares of common stock with a conversion price of $0.14286 per share. The Agreement and the issuance of the Series AA Preferred Stock were approved by the Company's board of directors and did not involve the exchange of consideration between the Company and Mr. Lazar beyond the terms set forth in the Agreement.
F2: Not applicable.
F3: Amount represents 5,740,000 shares received as a result of the conversion of 410,000 Series AA Convertible, Non-Redeemable Preferred Stock at a conversion price of $0.14286.
TITAN PHARMACEUTICALS INC
Report date July 26, 2023 · Filed July 31, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 100,000 |
Reported balance
After 2023-07-26 transaction · row 1
1 source rowRow 1 · 2023-07-26 · Grant · Acquired 100,000 · Balance 100,000 F1: The shares reported in this transaction represent Unrestricted Stock Awards pursuant to the Issuer's Fourth Amended and Restated 2015 Omnibus Equity Incentive Plan that vested immediately on the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares reported in this transaction represent Unrestricted Stock Awards pursuant to the Issuer's Fourth Amended and Restated 2015 Omnibus Equity Incentive Plan that vested immediately on the date of grant.
Tracon Pharmaceuticals, Inc.
Report date May 07, 2024 · Filed May 13, 2024
This filing explicitly reported no securities owned.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Bio Green Med Solution, Inc.
Report date July 30, 2025 · Filed August 04, 2025
Section 16 reporting ended · disclosed 2025-08-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 155,838 |
Reported balance
After 2025-07-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-07-30 · Sale · Disposed 6,750 · Balance 155,838 F1: The number Shares owned by the Reporting Person is reflective of a 1-for-15 reverse stock split effected by the Issuer on July 7, 2025 (the "Reverse Stock Split"). F2: Due to an inadvertent ministerial error, the Form 4 filed by the Reporting Person on February 28, 2025 reported beneficial ownership of 354,738 shares of the Issuer's Series D Convertible Preferred Stock which had already been converted into 162,588 shares of Common Stock (after giving effect to the Reverse Stock Split) as of such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The number Shares owned by the Reporting Person is reflective of a 1-for-15 reverse stock split effected by the Issuer on July 7, 2025 (the "Reverse Stock Split").
F2: Due to an inadvertent ministerial error, the Form 4 filed by the Reporting Person on February 28, 2025 reported beneficial ownership of 354,738 shares of the Issuer's Series D Convertible Preferred Stock which had already been converted into 162,588 shares of Common Stock (after giving effect to the Reverse Stock Split) as of such date.
LQR House Inc.
Report date April 02, 2025 · Filed April 07, 2025
Section 16 reporting ended · disclosed 2025-04-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 100,000 |
Reported balance
After 2025-04-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-04-02 · Grant · Acquired 100,000 · Balance 100,000 F1: On April 2, 2025, David Lazar (the "Reporting Person") resigned as President and as a member of the Board of Directors of the Issuer, effective immediately. In connection with his resignation, the Reporting Person and the Issuer entered into a Separation Agreement pursuant to which the Reporting Person received 100,000 shares of the Issuer's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 2, 2025, David Lazar (the "Reporting Person") resigned as President and as a member of the Board of Directors of the Issuer, effective immediately. In connection with his resignation, the Reporting Person and the Issuer entered into a Separation Agreement pursuant to which the Reporting Person received 100,000 shares of the Issuer's common stock.
Stablecoin Development Corp
Report date October 21, 2025 · Filed January 30, 2026
Section 16 reporting ended · disclosed 2026-01-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,388,000 |
Reported balance
After 2025-10-21 transaction · row 1
1 source rowRow 1 · 2025-10-21 · Grant · Acquired 6,388,000 · Balance 6,388,000 F1: The shares of Common Stock reported herein were issued upon the automatic conversion of the Series D Preferred Stock held by the Reporting Person three business days after the annual meeting of stockholders (the "Annual Meeting") of NovaBay Pharmaceuticals, Inc. (the "Issuer"), which occurred on October 16, 2025. |
| Series D Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-10-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-10-21 · Exercise / conversion · Disposed 39,925 · Balance 0 F2: The shares of Series D Preferred Stock are convertible at the option of the Reporting Person for no additional consideration. Each share of Series D Preferred Stock is convertible into 160 shares of the Issuer's Common Stock at any time, subject to certain ownership limitations. F4: On October 9, 2025, David E. Lazar (the "Reporting Person") entered into a Securities Purchase Agreement pursuant to which the the Reporting Person sold all of his title and interest in (i) an aggregate of 441,325 shares of Series D Preferred Stock for $9,850,000 and (ii) the rights and obligations to purchase 268,750 shares of Series E Preferred Stock for an additional $2,150,000 payable to the Issuer (the "October Transaction"). The closing of the October Transaction occurred on October 16, 2025 following the Issuer's Annual Meeting. Following the October Transaction, the Reporting Person retained 39,925 shares of Series D Preferred Stock, which automatically converted into shares of hte Issuer's Common Stock three business days after the Annual Meeting. F3: The Series D Preferred Stock is exercisable immediately upon issuance, is perpetual and has no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Common Stock reported herein were issued upon the automatic conversion of the Series D Preferred Stock held by the Reporting Person three business days after the annual meeting of stockholders (the "Annual Meeting") of NovaBay Pharmaceuticals, Inc. (the "Issuer"), which occurred on October 16, 2025.
F2: The shares of Series D Preferred Stock are convertible at the option of the Reporting Person for no additional consideration. Each share of Series D Preferred Stock is convertible into 160 shares of the Issuer's Common Stock at any time, subject to certain ownership limitations.
F3: The Series D Preferred Stock is exercisable immediately upon issuance, is perpetual and has no expiration date.
F4: On October 9, 2025, David E. Lazar (the "Reporting Person") entered into a Securities Purchase Agreement pursuant to which the the Reporting Person sold all of his title and interest in (i) an aggregate of 441,325 shares of Series D Preferred Stock for $9,850,000 and (ii) the rights and obligations to purchase 268,750 shares of Series E Preferred Stock for an additional $2,150,000 payable to the Issuer (the "October Transaction"). The closing of the October Transaction occurred on October 16, 2025 following the Issuer's Annual Meeting. Following the October Transaction, the Reporting Person retained 39,925 shares of Series D Preferred Stock, which automatically converted into shares of hte Issuer's Common Stock three business days after the Annual Meeting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 22, 2024 Filed Jan 24, 2024 22:10 UTC | FiEE, Inc. MINM · Entity 7395 | GrantCommon Stock | 25,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000921895-24-000127 · form412227016laz_01242024.xml · nonDerivative · entry 1 Lazar David E. · CIK 0001932843 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 F1 · price: Shares of restricted stock issued pursuant to the Non-Employee Directors Compensation Plan of Minim, Inc. (the "Company"). F2 · balance_after: The amounts reflected in this Form 4 do not include shares of convertible preferred stock that the Reporting Person will receive upon to the closing of a securities purchase agreement between the Reporting Person and the Company. Read SEC document |
| July 26, 2023 Filed Jul 31, 2023 19:39 UTC | TITAN PHARMACEUTICALS INC TTNP · Entity 74432 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-23-001766 · form413531laz_07282023.xml · nonDerivative · entry 1 Lazar David E. · CIK 0001932843 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 F1 · shares: The shares reported in this transaction represent Unrestricted Stock Awards pursuant to the Issuer's Fourth Amended and Restated 2015 Omnibus Equity Incentive Plan that vested immediately on the date of grant. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 16:07 UTC | TITAN PHARMACEUTICALS INC TTNP · Entity 74432 | SaleCommon Stock, par value $0.001 | 359,066 | $1.23 | $441,651.18 |
DisclosureSEC source: 0000921895-23-001569 · form413531001_06222023.xml · nonDerivative · entry 2 Lazar David E. · CIK 0001932843 · Director · Chief Executive Officer · 10% owner Activist Investing LLC · CIK 0001817604 · Member of 10% owner group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Activist Investing LLC Disclosed balance after: 0 F1 · price: These Shares were sold pursuant to a Share Transfer Agreement dated June 21, 2023. As consideration for the transfer, Mr. Lazar received $4,600,000. F2 · ownership.nature: This Form 4 is filed jointly by Activist Investing LLC ("Activist Investing") and David E. Lazar (collectively, the "Reporting Persons"). F3 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities of the Issuer reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 or any other purpose. F4 · ownership.nature: Securities of the Issuer beneficially owned directly by Activist Investing. Mr. Lazar, as the sole member and Chief Executive Officer of Activist Investing, may be deemed the beneficial owner of the securities of the Issuer beneficially owned by Activist Investing. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 16:07 UTC | TITAN PHARMACEUTICALS INC TTNP · Entity 74432 | SaleCommon Stock, par value $0.001 | 3,388,902 | $1.23 | $4,168,349.46 |
DisclosureSEC source: 0000921895-23-001569 · form413531001_06222023.xml · nonDerivative · entry 1 Lazar David E. · CIK 0001932843 · Director · Chief Executive Officer · 10% owner Activist Investing LLC · CIK 0001817604 · Member of 10% owner group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: These Shares were sold pursuant to a Share Transfer Agreement dated June 21, 2023. As consideration for the transfer, Mr. Lazar received $4,600,000. F2 · ownership.direct: This Form 4 is filed jointly by Activist Investing LLC ("Activist Investing") and David E. Lazar (collectively, the "Reporting Persons"). F3 · ownership.direct: Each Reporting Person disclaims beneficial ownership of the securities of the Issuer reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 or any other purpose. Read SEC document |
| June 21, 2023 Filed Jun 28, 2023 16:14 UTC Amendment | TITAN PHARMACEUTICALS INC TTNP · Entity 74432 | SaleCommon Stock, par value $0.001 | 359,066 | $1.23 | $441,651.18 |
DisclosureSEC source: 0000921895-23-001593 · form4a113531laz_06272023.xml · nonDerivative · entry 2 Lazar David E. · CIK 0001932843 · Director · Chief Executive Officer · 10% owner Activist Investing LLC · CIK 0001817604 · Member of 10% owner group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Activist Investing LLC Disclosed balance after: 0 F1 · price: These Shares were sold pursuant to a Share Transfer Agreement dated June 21, 2023. As consideration for the transfer, Mr. Lazar received $4,600,000. F2 · price: Prior to the filing of the Reporting Persons's Form 4 on June 23, 2023, the Reporting Person contacted the Issuer and advised the Issuer of his obligation to disgorge the "short-swing profit" realized by the Reporting Person, and that he was making preparation for payment of such disgorgement. Due to a ministerial error, such informaton was inadvertently excluded from the Form 4 filed by the Reporting Person on June 23, 2023. F3 · ownership.nature: This Form 4 is filed jointly by Activist Investing LLC ("Activist Investing") and David E. Lazar (collectively, the "Reporting Persons"). F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities of the Issuer reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 or any other purpose. F5 · ownership.nature: Securities of the Issuer beneficially owned directly by Activist Investing. Mr. Lazar, as the sole member and Chief Executive Officer of Activist Investing, may be deemed the beneficial owner of the securities of the Issuer beneficially owned by Activist Investing. Read SEC document |
| June 21, 2023 Filed Jun 28, 2023 16:14 UTC Amendment | TITAN PHARMACEUTICALS INC TTNP · Entity 74432 | SaleCommon Stock, par value $0.001 | 3,388,902 | $1.23 | $4,168,349.46 |
DisclosureSEC source: 0000921895-23-001593 · form4a113531laz_06272023.xml · nonDerivative · entry 1 Lazar David E. · CIK 0001932843 · Director · Chief Executive Officer · 10% owner Activist Investing LLC · CIK 0001817604 · Member of 10% owner group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: These Shares were sold pursuant to a Share Transfer Agreement dated June 21, 2023. As consideration for the transfer, Mr. Lazar received $4,600,000. F2 · price: Prior to the filing of the Reporting Persons's Form 4 on June 23, 2023, the Reporting Person contacted the Issuer and advised the Issuer of his obligation to disgorge the "short-swing profit" realized by the Reporting Person, and that he was making preparation for payment of such disgorgement. Due to a ministerial error, such informaton was inadvertently excluded from the Form 4 filed by the Reporting Person on June 23, 2023. F3 · ownership.direct: This Form 4 is filed jointly by Activist Investing LLC ("Activist Investing") and David E. Lazar (collectively, the "Reporting Persons"). F4 · ownership.direct: Each Reporting Person disclaims beneficial ownership of the securities of the Issuer reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 or any other purpose. Read SEC document |
| January 25, 2023 Filed Jan 26, 2023 13:05 UTC | TITAN PHARMACEUTICALS INC TTNP · Entity 74432 | PurchaseCommon Stock, par value $0.001 | 20,000 | $1.00 | $20,066.00 |
DisclosureSEC source: 0000921895-23-000200 · form413531laz_01262023.xml · nonDerivative · entry 2 Lazar David E. · CIK 0001932843 · Director · Chief Executive Officer · 10% owner Activist Investing LLC · CIK 0001817604 · Member of 10% owner group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,388,902 F4 · price: Represents a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $0.97 to $1.01. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.direct: This Form 4 is filed jointly by Activist Investing LLC ("Activist Investing") and David E. Lazar (collectively, the "Reporting Persons"). F3 · ownership.direct: Each Reporting Person disclaims beneficial ownership of the securities of the Issuer reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 or any other purpose. Read SEC document |
| January 24, 2023 Filed Jan 26, 2023 13:05 UTC | TITAN PHARMACEUTICALS INC TTNP · Entity 74432 | PurchaseCommon Stock, par value $0.001 | 37,500 | $0.97 | $36,221.25 |
DisclosureSEC source: 0000921895-23-000200 · form413531laz_01262023.xml · nonDerivative · entry 1 Lazar David E. · CIK 0001932843 · Director · Chief Executive Officer · 10% owner Activist Investing LLC · CIK 0001817604 · Member of 10% owner group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,368,902 F1 · price: Represents a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $0.9591 to $0.98. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.direct: This Form 4 is filed jointly by Activist Investing LLC ("Activist Investing") and David E. Lazar (collectively, the "Reporting Persons"). F3 · ownership.direct: Each Reporting Person disclaims beneficial ownership of the securities of the Issuer reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 or any other purpose. Read SEC document |
| July 07, 2022 Filed Jul 8, 2022 18:00 UTC | TITAN PHARMACEUTICALS INC TTNP · Entity 74432 | PurchaseCommon Stock, par value $0.001 | 744,294 | $0.99 | $739,009.51 |
DisclosureSEC source: 0001829126-22-014209 · ownership.xml · nonDerivative · entry 2 Lazar David E. · CIK 0001932843 · 10% owner Activist Investing LLC · CIK 0001817604 · Member of 10% owner group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,331,402 F4 · price: Represents a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $0.8399 to $1.1000. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within the range set forth in this footnote. F1 · ownership.direct: This Form 4 is filed jointly by Activist Investing LLC ("Activist Investing") and David E. Lazar (collectively, the "Reporting Persons"). F2 · ownership.direct: Each Reporting Person disclaims beneficial ownership of the securities of the Issuer reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 or any other purpose. Read SEC document |
| July 06, 2022 Filed Jul 8, 2022 18:00 UTC | TITAN PHARMACEUTICALS INC TTNP · Entity 74432 | PurchaseCommon Stock, par value $0.001 | 315,921 | $0.89 | $281,991.08 |
DisclosureSEC source: 0001829126-22-014209 · ownership.xml · nonDerivative · entry 3 Lazar David E. · CIK 0001932843 · 10% owner Activist Investing LLC · CIK 0001817604 · Member of 10% owner group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Activist Investing LLC Disclosed balance after: 359,066 F6 · price: Represents a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $0.6640 to $0.9499. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within the range set forth in this footnote. F1 · ownership.nature: This Form 4 is filed jointly by Activist Investing LLC ("Activist Investing") and David E. Lazar (collectively, the "Reporting Persons"). F2 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities of the Issuer reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 or any other purpose. F5 · ownership.nature: Securities of the Issuer beneficially owned directly by Activist Investing. Mr. Lazar, as the sole member and Chief Executive Officer of Activist Investing, may be deemed the beneficial owner of the securities of the Issuer beneficially owned by Activist Investing. Read SEC document |
| July 06, 2022 Filed Jul 8, 2022 18:00 UTC | TITAN PHARMACEUTICALS INC TTNP · Entity 74432 | PurchaseCommon Stock, par value $0.001 | 1,165,975 | $0.77 | $901,881.66 |
DisclosureSEC source: 0001829126-22-014209 · ownership.xml · nonDerivative · entry 1 Lazar David E. · CIK 0001932843 · 10% owner Activist Investing LLC · CIK 0001817604 · Member of 10% owner group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,587,108 F3 · price: Represents a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $0.5982 to $0.9964. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within the range set forth in this footnote. F1 · ownership.direct: This Form 4 is filed jointly by Activist Investing LLC ("Activist Investing") and David E. Lazar (collectively, the "Reporting Persons"). F2 · ownership.direct: Each Reporting Person disclaims beneficial ownership of the securities of the Issuer reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 or any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.